mechanism glp 1 receptor agonist Frontiers Frontiers | GLP−1 receptor agonists
Description
Consistency matters more than perfection
In a separate study involving 190 patients receiving 52 weeks of treatment, remission rates were 36.8%, 45.6%, and 52.0% for the 5, 10, and 15 mg tirzepatide groups, respectively, compared to 18.2% in the placebo group (Loomba et al., 2024)
Mol Metab 28, 1425 (2019)
Here is what happens in sequence
The slow adoption of anti-obesity treatments may be a spill-over of unfavorable past experiences
